640 related articles for article (PubMed ID: 32227567)
41. Comparison of refugee patients with cystic fibrosis and their counterpart children from Turkey during the war.
Yılmaz Aİ; Pekcan S; Eyüboğlu TŞ; Hangül M; Arslan H; Kılınç AA; Çokuğraş H; Arık E; Keskin Ö; Özdemir A; Ersoy M; Ersoy A; Köse M; Özsezen B; Ünal G; Ercan Ö; Girit S; Oksay SC; Gökdemir Y; Karadağ B; Şen V; Çakır E; Yüksel H; Tekin MN; Aslan AT
Eur J Pediatr; 2024 Apr; 183(4):1831-1838. PubMed ID: 38265526
[TBL] [Abstract][Full Text] [Related]
42. A pediatric cystic fibrosis arthropathy case who responded to Elexacaftor/Tezacaftor/Ivacaftor therapy.
Arslan M; Bahadir Z; Basiaga ML; Chalmers SJ; Demirel N
J Cyst Fibros; 2023 Nov; 22(6):1120-1122. PubMed ID: 37709627
[TBL] [Abstract][Full Text] [Related]
43. A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation.
Knott-Torcal C; Sebastián-Valles F; Girón Moreno RM; Martín-Adán JC; Jiménez-Díaz J; Marazuela M; Sánchez de la Blanca N; Fernández-Contreras R; Arranz-Martín A
Clin Nutr; 2023 Dec; 42(12):2468-2474. PubMed ID: 38411018
[TBL] [Abstract][Full Text] [Related]
44. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG
Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355
[TBL] [Abstract][Full Text] [Related]
45. Benign and Deleterious Cystic Fibrosis Transmembrane Conductance Regulator Mutations Identified by Sequencing in Positive Cystic Fibrosis Newborn Screen Children from California.
Salinas DB; Sosnay PR; Azen C; Young S; Raraigh KS; Keens TG; Kharrazi M
PLoS One; 2016; 11(5):e0155624. PubMed ID: 27214204
[TBL] [Abstract][Full Text] [Related]
46. Phenotypic spectrum of patients with cystic fibrosis and cystic fibrosis-related disease carrying p.Arg117His.
Keenan K; Dupuis A; Griffin K; Castellani C; Tullis E; Gonska T
J Cyst Fibros; 2019 Mar; 18(2):265-270. PubMed ID: 30279124
[TBL] [Abstract][Full Text] [Related]
47. Personalized CFTR Modulator Therapy for
Graeber SY; Balázs A; Ziegahn N; Rubil T; Vitzthum C; Piehler L; Drescher M; Seidel K; Rohrbach A; Röhmel J; Thee S; Duerr J; Mall MA; Stahl M
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569738
[TBL] [Abstract][Full Text] [Related]
48. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype.
McGarry ME; McColley SA
Pediatr Pulmonol; 2021 Jun; 56(6):1496-1503. PubMed ID: 33470563
[TBL] [Abstract][Full Text] [Related]
49. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
Brewington JJ; McPhail GL; Clancy JP
Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
[TBL] [Abstract][Full Text] [Related]
50. Clinical Sensitivity of Cystic Fibrosis Mutation Panels in a Diverse Population.
Hughes EE; Stevens CF; Saavedra-Matiz CA; Tavakoli NP; Krein LM; Parker A; Zhang Z; Maloney B; Vogel B; DeCelie-Germana J; Kier C; Anbar RD; Berdella MN; Comber PG; Dozor AJ; Goetz DM; Guida L; Kattan M; Ting A; Voter KZ; ; van Roey P; Caggana M; Kay DM
Hum Mutat; 2016 Feb; 37(2):201-8. PubMed ID: 26538069
[TBL] [Abstract][Full Text] [Related]
51. Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome.
Ren CL; Desai H; Platt M; Dixon M
Pediatr Pulmonol; 2011 Nov; 46(11):1079-84. PubMed ID: 21538969
[TBL] [Abstract][Full Text] [Related]
52. Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses.
Sosnay PR; Salinas DB; White TB; Ren CL; Farrell PM; Raraigh KS; Girodon E; Castellani C
J Pediatr; 2017 Feb; 181S():S27-S32.e1. PubMed ID: 28129809
[TBL] [Abstract][Full Text] [Related]
53. Molecular Diagnosis and Genetic Counseling of Cystic Fibrosis and Related Disorders: New Challenges.
Bienvenu T; Lopez M; Girodon E
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32512765
[TBL] [Abstract][Full Text] [Related]
54. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
[TBL] [Abstract][Full Text] [Related]
55. Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators.
Colombo C; Ramm GA; Lindblad A; Corti F; Porcaro L; Alghisi F; Asherova I; Evans H; Kashirskaya N; Kondratyeva E; Lewindon PJ; de Monestrol I; Oliver M; Ooi CY; Padoan R; Shankar S; Alicandro G
J Cyst Fibros; 2023 Mar; 22(2):263-265. PubMed ID: 36739240
[TBL] [Abstract][Full Text] [Related]
56. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS
N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344
[TBL] [Abstract][Full Text] [Related]
57. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
58. Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients.
Pique L; Graham S; Pearl M; Kharrazi M; Schrijver I
Genet Med; 2017 Jan; 19(1):36-44. PubMed ID: 27148940
[TBL] [Abstract][Full Text] [Related]
59. Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels?
Scotet V; Audrézet MP; Roussey M; Rault G; Dirou-Prigent A; Journel H; Moisan-Petit V; Storni V; Férec C
Pediatrics; 2006 Nov; 118(5):e1523-9. PubMed ID: 17015492
[TBL] [Abstract][Full Text] [Related]
60. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
